MAGE-3 (113-121)

MAGE-3 (113-121) is a synthetic peptide fragment derived from the melanoma-associated antigen 3 (MAGE-3) protein, specifically encompassing amino acids 113 to 121 of the parent sequence. As a member of the cancer-testis antigen family, MAGE-3 is characterized by its restricted expression in normal tissues and elevated presence in various tumor types, making it a significant target in tumor immunology research. The 113-121 epitope represents a well-defined segment that is frequently investigated for its immunogenic properties and its ability to bind to major histocompatibility complex (MHC) molecules. Owing to its defined sequence and strong immunological relevance, this peptide plays a crucial role in studies exploring antigen presentation, T cell recognition, and the development of novel immunotherapeutic strategies.

Immunological assay development: The 113-121 peptide fragment of MAGE-3 is widely utilized in the design and optimization of immunological assays that evaluate antigen-specific T cell responses. By serving as a defined epitope, it enables researchers to monitor cytotoxic T lymphocyte (CTL) activation, assess peptide-MHC binding affinities, and quantify immune reactivity in vitro. These assays are foundational for dissecting cellular immune mechanisms and for validating the immunogenicity of candidate epitopes in preclinical models.

Epitope mapping and antigen presentation studies: Researchers employ this peptide in epitope mapping experiments to delineate the precise regions of MAGE-3 recognized by T cell receptors. Its defined sequence allows for systematic investigation into the molecular interactions governing antigen processing and presentation via MHC class I molecules. Such studies provide valuable insight into the determinants of immunodominance and inform the selection of optimal peptide candidates for immunotherapy research.

Peptide-based vaccine research: The MAGE-3 (113-121) sequence is frequently incorporated into experimental peptide vaccine formulations aimed at eliciting targeted cellular immune responses. By leveraging its capacity to stimulate antigen-specific CTLs, investigators can assess vaccine efficacy, optimize adjuvant combinations, and explore mechanisms of immune memory induction. These investigations contribute to the rational design of next-generation cancer vaccines and personalized immunotherapeutic approaches.

Synthetic peptide library screening: As part of larger synthetic peptide libraries, the 113-121 fragment serves as a reference or comparator for high-throughput screening platforms. Its inclusion enables the identification of cross-reactive T cell populations, the evaluation of sequence variants, and the discovery of novel immunogenic peptides. This approach supports the development of peptide-based diagnostics and enhances the understanding of T cell repertoire diversity in the context of tumor-associated antigens.

Cellular immunology model systems: The defined nature of the MAGE-3 (113-121) peptide makes it an ideal tool for establishing in vitro model systems that investigate the dynamics of antigen-specific immune responses. Researchers utilize it to generate and expand CTL lines, study T cell receptor specificity, and analyze the functional consequences of peptide-MHC interactions. These model systems are instrumental in elucidating the molecular basis of immune recognition and in advancing translational research efforts in tumor immunology.

1. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

2. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists

3. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis

5. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes